<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362442">
  <stage>Registered</stage>
  <submitdate>27/04/2012</submitdate>
  <approvaldate>2/05/2012</approvaldate>
  <actrnumber>ACTRN12612000482864</actrnumber>
  <trial_identification>
    <studytitle>Comparison trial of three needle-free devices for application of intradermal inactivated polio vaccine in young infants in Cuba</studytitle>
    <scientifictitle>Comparison of immune response of fractional inactivated poliovirus vaccine (IPV) administered intradermally using different administration techniques in young infants in Camaguey, Cuba</scientifictitle>
    <utrn>U1111-1130-3070</utrn>
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>poliomyelitis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Epidemiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intradermal administration of single fractional dose of inactivated polio vaccine via BCG needle or one of three different needle-free devices.

There are 4 interventional arms (in each arm one IPV dose is administered):

1 - fIPV intradermally through BCG syringe (fractional dose - 0.1ml)
2 - fIPV Device A (Biojector 2000, dose 0.1 ml)
3 - fIPV Device B (Bioject ID Pen, dose 0.1 ml)
4 - fIPV Device C (Pharmajet, dose 0.1 ml)</interventions>
    <comparator>Intramuscular administration of one full dose of inactivated polio vaccine (0.5 ml) using standard auto-destruct needle and syringe.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is seroconversion or boost of polio antibodies by neutralization assay on day 28  compared to day 0</outcome>
      <timepoint>Day 28 from enrollment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Seroconversion or boost of antibodies by neutralization assay on days 3 and 7.</outcome>
      <timepoint>Day 3 and Day 7 from enrollment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of priming immune response after the first dose of IPV by neutralization assay.</outcome>
      <timepoint>Day 7 from enrollment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy infants born between July 1 and December 31, 2011 (&gt;3rd percentile for height and weight) at enrollment living within the catchments area of the participating health centers with documented history of receiving two doses of OPV through NIDs in 2012.</inclusivecriteria>
    <inclusiveminage>9</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Infants &lt;3 percentile for height and weight, residence outside the catchments area, or families expecting to move away during the study period, will be excluded. A diagnosis, suspicion or treatment of immunodeficiency disorder (either in the participant or in a member of the immediate family) will render the newborn ineligible for the study. Infants of mother age below legal age (&lt;18 years) or with mentally incapacity will not be eligible to participate.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/09/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Cuba</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>World Health Organization</primarysponsorname>
    <primarysponsoraddress>Avenue Appia 20
CH-1211 Geneva 27</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>World Health Organization</fundingname>
      <fundingaddress>Avenue Appia 20
CH-1211 Geneva 27</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Instituto Pedro Kouri (IPK), Habana, Cuba</othercollaboratorname>
      <othercollaboratoraddress>Marianao 13, Ciudad de La Habana</othercollaboratoraddress>
      <othercollaboratorcountry>Cuba</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will inform on polio eradication prerequisite regarding implementation of IPV requirements in countries that retain poliovirus in laboratories or in production as well as on the performance and usability of three different needle-free devices to deliver fractional dose IPV (affordable IPV) in routine immunization programs as well as during vaccination campaigns.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ERC of the World Health Organization</ethicname>
      <ethicaddress>Avenue Appia 20
CH-1211 Geneva 27</ethicaddress>
      <ethicapprovaldate />
      <hrec>RPC506</hrec>
      <ethicsubmitdate>16/04/2012</ethicsubmitdate>
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ondrej Mach</name>
      <address>WHO
Avenue Appia 20
CH-1211 Geneva 27</address>
      <phone>+41227911863</phone>
      <fax />
      <email>macho@who.int</email>
      <country>Switzerland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ondrej Mach</name>
      <address>WHO
Avenue Appia 20
CH-1211 Geneva 27</address>
      <phone>+41227911863</phone>
      <fax />
      <email>macho@who.int</email>
      <country>Switzerland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>